GALAPAGOS NV/S (NASDAQ:GLPG) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $152.00 target price on the biotechnology company’s stock.
According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
Several other research firms also recently commented on GLPG. Morgan Stanley increased their target price on Thomson Reuters from $66.00 to $67.00 and gave the company an overweight rating in a research report on Monday, April 29th. ValuEngine upgraded XPO Logistics from a strong sell rating to a sell rating in a research report on Thursday, April 4th. BidaskClub downgraded Amyris from a hold rating to a sell rating in a research report on Thursday, June 27th. HC Wainwright set a $10.00 target price on Jaguar Health and gave the company a buy rating in a research report on Tuesday, July 2nd. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $25.00 target price on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. One analyst has rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $134.90.
GALAPAGOS NV/S (NASDAQ:GLPG) last posted its earnings results on Friday, April 26th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.18. The firm had revenue of $46.47 million during the quarter, compared to the consensus estimate of $44.92 million. GALAPAGOS NV/S had a negative return on equity of 3.60% and a negative net margin of 13.24%. On average, equities research analysts forecast that GALAPAGOS NV/S will post -4.61 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC lifted its stake in shares of GALAPAGOS NV/S by 35.3% in the 1st quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock valued at $59,148,000 after acquiring an additional 131,119 shares during the last quarter. Marshall Wace North America L.P. raised its position in GALAPAGOS NV/S by 149.4% during the 1st quarter. Marshall Wace North America L.P. now owns 18,751 shares of the biotechnology company’s stock valued at $2,208,000 after purchasing an additional 11,233 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in GALAPAGOS NV/S by 121.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 6,200 shares of the biotechnology company’s stock valued at $632,000 after purchasing an additional 3,400 shares during the last quarter. Pinnacle Associates Ltd. bought a new position in GALAPAGOS NV/S during the 1st quarter valued at approximately $231,000. Finally, Stevens Capital Management LP bought a new position in GALAPAGOS NV/S during the 1st quarter valued at approximately $398,000. Institutional investors own 16.33% of the company’s stock.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
See Also: Why are trading ranges significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.